IN2014CN02153A - - Google Patents
Info
- Publication number
- IN2014CN02153A IN2014CN02153A IN2153CHN2014A IN2014CN02153A IN 2014CN02153 A IN2014CN02153 A IN 2014CN02153A IN 2153CHN2014 A IN2153CHN2014 A IN 2153CHN2014A IN 2014CN02153 A IN2014CN02153 A IN 2014CN02153A
- Authority
- IN
- India
- Prior art keywords
- scleral
- corneal
- pdt
- chlorophyll
- anomalies
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002428 photodynamic therapy Methods 0.000 abstract 2
- 206010054760 Corneal thinning Diseases 0.000 abstract 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 abstract 1
- 229930002875 chlorophyll Natural products 0.000 abstract 1
- 235000019804 chlorophyll Nutrition 0.000 abstract 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An ophthalmic composition is provided comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases disorders and conditions associated with corneal or scleral anomalies such as corneal thinning and scleral stretching.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526414P | 2011-08-23 | 2011-08-23 | |
| PCT/IL2012/050325 WO2013027222A1 (en) | 2011-08-23 | 2012-08-23 | (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02153A true IN2014CN02153A (en) | 2015-05-29 |
Family
ID=46889394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2153CHN2014 IN2014CN02153A (en) | 2011-08-23 | 2012-08-23 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9452172B2 (en) |
| EP (1) | EP2747763B1 (en) |
| JP (1) | JP6215203B2 (en) |
| KR (1) | KR101962991B1 (en) |
| CN (1) | CN103930108B (en) |
| AU (1) | AU2012298156B2 (en) |
| BR (1) | BR112014004306A2 (en) |
| CA (1) | CA2846011C (en) |
| CL (1) | CL2014000432A1 (en) |
| DK (1) | DK2747763T3 (en) |
| ES (1) | ES2856698T3 (en) |
| HK (1) | HK1199412A1 (en) |
| HU (1) | HUE053321T2 (en) |
| IN (1) | IN2014CN02153A (en) |
| MX (1) | MX360683B (en) |
| PE (1) | PE20141183A1 (en) |
| PT (1) | PT2747763T (en) |
| RU (1) | RU2632439C2 (en) |
| WO (1) | WO2013027222A1 (en) |
| ZA (1) | ZA201402056B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| EP2729180B1 (en) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| EP2830637A4 (en) | 2012-03-29 | 2016-03-16 | Cxl Ophthalmics Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| RU2635185C2 (en) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Pharmaceutical preparation for prevention and treatment of progressive myopia |
| WO2017015471A1 (en) | 2015-07-21 | 2017-01-26 | Avedro, Inc. | Systems and methods for treaments of an eye with a photosensitizer |
| CN106620893B (en) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | Materials for ocular disease phototherapy |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| CN105601638B (en) * | 2016-01-28 | 2018-10-26 | 东北林业大学 | A kind of chlorophyllin derivative and preparation method thereof, as the application of photosensitive bacteriostatic agent and light sensitive pesticides |
| EP3442481B1 (en) | 2016-04-13 | 2023-06-28 | Avedro, Inc. | Systems for delivering drugs to an eye |
| US20170319329A1 (en) * | 2016-05-05 | 2017-11-09 | David Muller | Corneal Implant Systems and Methods |
| EP3565512A1 (en) * | 2017-01-03 | 2019-11-13 | Vitrean, Inc. | Methods and devices for treating a retinal detachment |
| EP3638367A4 (en) * | 2017-08-02 | 2021-07-21 | The University of Chicago | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| CN109091685A (en) * | 2018-08-10 | 2018-12-28 | 北京市眼科研究所 | A kind of pair of keratitis extracts the ablation method of bacterial pathogens |
| US11702546B2 (en) | 2018-10-24 | 2023-07-18 | California Institute Of Technology | Near-infrared heptamethine dyes for generation of singlet oxygen |
| US20200129620A1 (en) * | 2018-10-24 | 2020-04-30 | California Institute Of Technology | Treatment Of Myopia And Other Ocular Conditions Using Singlet Oxygen Generated From Dyes Activated By Near-Infrared Light |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102645A (en) | 1992-07-26 | 1998-02-22 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| RU2201219C2 (en) * | 2001-04-24 | 2003-03-27 | Макаров Константин Алексеевич | Pharmacological composition with prolonged effect |
| WO2003028628A2 (en) * | 2001-10-03 | 2003-04-10 | Miravant Pharmaceuticals, Inc. | Photosensitizing carbamate derivatives |
| IL152900A0 (en) | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| CA2569675C (en) * | 2004-06-07 | 2015-03-17 | Yeda Research And Development Co. Ltd | Cationic bacteriochlorophyll derivatives and uses thereof |
| DK2061512T3 (en) * | 2006-08-23 | 2020-01-20 | Yeda Res & Dev | CONJUGATES OF RGD PEPTIDES AND (BACTERY) CHLOROPHYL PHOTOSENSIBILITORS AND USES THEREOF |
| KR101551590B1 (en) | 2006-10-24 | 2015-09-08 | 캘리포니아 인스티튜트 오브 테크놀로지 | Photochemical therapy to affect mechanical and/or chemical properties of body tissue |
| RU2404768C1 (en) * | 2009-10-28 | 2010-11-27 | Федеральное агентство по науке и инновациям | Eye drops |
| WO2011099602A1 (en) * | 2010-02-12 | 2011-08-18 | 学校法人日本大学 | Porphyrin derivative and use thereof in radiation induced photodynamic therapy |
-
2012
- 2012-08-23 JP JP2014526601A patent/JP6215203B2/en active Active
- 2012-08-23 MX MX2014002107A patent/MX360683B/en active IP Right Grant
- 2012-08-23 HU HUE12762405A patent/HUE053321T2/en unknown
- 2012-08-23 PT PT127624054T patent/PT2747763T/en unknown
- 2012-08-23 IN IN2153CHN2014 patent/IN2014CN02153A/en unknown
- 2012-08-23 BR BR112014004306A patent/BR112014004306A2/en not_active IP Right Cessation
- 2012-08-23 AU AU2012298156A patent/AU2012298156B2/en not_active Ceased
- 2012-08-23 EP EP12762405.4A patent/EP2747763B1/en active Active
- 2012-08-23 CA CA2846011A patent/CA2846011C/en active Active
- 2012-08-23 RU RU2014110784A patent/RU2632439C2/en active
- 2012-08-23 DK DK12762405.4T patent/DK2747763T3/en active
- 2012-08-23 US US14/240,328 patent/US9452172B2/en active Active
- 2012-08-23 KR KR1020147007481A patent/KR101962991B1/en active IP Right Grant
- 2012-08-23 WO PCT/IL2012/050325 patent/WO2013027222A1/en active Application Filing
- 2012-08-23 PE PE2014000246A patent/PE20141183A1/en not_active Application Discontinuation
- 2012-08-23 CN CN201280045801.9A patent/CN103930108B/en active Active
- 2012-08-23 ES ES12762405T patent/ES2856698T3/en active Active
-
2014
- 2014-02-21 CL CL2014000432A patent/CL2014000432A1/en unknown
- 2014-03-20 ZA ZA2014/02056A patent/ZA201402056B/en unknown
- 2014-12-31 HK HK14113090.6A patent/HK1199412A1/en unknown
-
2016
- 2016-08-18 US US15/240,221 patent/US20160354468A1/en not_active Abandoned
-
2018
- 2018-11-20 US US16/196,537 patent/US11058772B2/en active Active
-
2021
- 2021-07-08 US US17/370,743 patent/US20210330792A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2632439C2 (en) | 2017-10-04 |
| HK1199412A1 (en) | 2015-07-03 |
| PE20141183A1 (en) | 2014-10-05 |
| ES2856698T3 (en) | 2021-09-28 |
| CN103930108A (en) | 2014-07-16 |
| AU2012298156B2 (en) | 2017-08-17 |
| CA2846011C (en) | 2019-10-15 |
| JP2014524465A (en) | 2014-09-22 |
| US20160354468A1 (en) | 2016-12-08 |
| US20210330792A1 (en) | 2021-10-28 |
| MX2014002107A (en) | 2015-04-16 |
| JP6215203B2 (en) | 2017-10-18 |
| EP2747763A1 (en) | 2014-07-02 |
| RU2014110784A (en) | 2015-09-27 |
| DK2747763T3 (en) | 2021-03-29 |
| US20190231874A1 (en) | 2019-08-01 |
| MX360683B (en) | 2018-11-13 |
| BR112014004306A2 (en) | 2017-03-28 |
| US20140378888A1 (en) | 2014-12-25 |
| CA2846011A1 (en) | 2013-02-28 |
| CN103930108B (en) | 2017-05-24 |
| US11058772B2 (en) | 2021-07-13 |
| CL2014000432A1 (en) | 2014-11-28 |
| HUE053321T2 (en) | 2021-06-28 |
| AU2012298156A1 (en) | 2014-04-10 |
| US9452172B2 (en) | 2016-09-27 |
| KR101962991B1 (en) | 2019-03-27 |
| ZA201402056B (en) | 2015-11-25 |
| WO2013027222A1 (en) | 2013-02-28 |
| EP2747763B1 (en) | 2020-12-30 |
| KR20140088514A (en) | 2014-07-10 |
| PT2747763T (en) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02153A (en) | ||
| MX347226B (en) | Treatment of ocular disease. | |
| BR112017024531A2 (en) | light-adjustable intraocular lenses using upward conversion nanoparticles and near infrared light (nir) | |
| IL235446A0 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| IL227412A (en) | Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions | |
| MY175318A (en) | Androgen composition for treating an opthalmic condition | |
| EA201301277A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF MESH DISEASES | |
| MX2015002239A (en) | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions. | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| EA201490721A1 (en) | Drug for the treatment of diseases of the anterior chamber of the eye, including rebamipid and tear-retaining agent | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| UA113627C2 (en) | CRYSTAL FORM OF CYCLOSPORIN A, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
| NZ704178A (en) | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions | |
| TR201900863T4 (en) | Reduction of central corneal thickening by using hydrophilic ester prodrugs of beta-chlorocyclopentanes. | |
| EA201490845A1 (en) | IMPROVED BONDING COMPOSITION DELIVERED BY METHOD OF IONTOPHORESIS, SUITABLE FOR THE TREATMENT OF KERATOCONUS | |
| UY34843A (en) | TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD | |
| MX2019011925A (en) | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension. | |
| CL2011001812A1 (en) | Use of deferiprone to prevent and treat an iron-related eye disorder selected from: age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, hereditary retinal degeneration, retinal detachment, ischemic retinopathy, among others. | |
| AR107460A1 (en) | GABAPENTINA OFTÁLMICA FOR THE TREATMENT OF CORNEAL ULCERS | |
| WO2014003850A3 (en) | Methods for treatment of ocular diseases | |
| CR11644A (en) | TREATMENT FOR EYE-RELATED DISORDERS | |
| EA201690903A1 (en) | TREATMENT GLAUCOMA USING LAQUINIMODE | |
| UA38111U (en) | Method for preoperative preparation of patients with myopia of high degree to the phacoemulsification of lens with implantation of intraocular lens | |
| RU2013125864A (en) | HIGH DEGREE PROGRESSING MYOPIA TREATMENT METHOD | |
| UA81136U (en) | Method for therapeutic autoscleroplasty of cornea |